Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Irinotecan (CPT-11, camptosar)
- Treatment of metastatic CRC
- Safety of irinotecan (1)
- Safety of irinotecan (2)
- Illustration of metabolic pathway of irinotecan
- Glucuronidation of SN-38 vs. toxicity
- Schematic illustration of UGT1A
- Candidate polymorphism: UGT1A1*28, (TA)7
- UGT1A1*28 genotype-phenotype association (1)
- UGT1A1*28 genotype-phenotype association (2)
- Revised irinotecan package insert (Mar 2005)
- Invader: UGT1A1molecular assay (Aug 2005)
- Role of UGT1A1*28 in metastatic CRC
- Unanswered questions
- UGT1A1*28 frequency in 3 different ethnic groups
- Another candidate polymorphism: UGT1A1*7
- Frequency of UGT1A1*6 in Asians
- UGT1A1*6 genotype-phenotype association
- Efficacy in UGT1A1*28-genotyped patients
- Irinotecan dose and hematologic toxicity
- Individualization of chemotherapy
- Genotype-based dosing of irinotecan (1)
- Genotype-based dosing of irinotecan (2)
- Role of other UGT1A
- Metabolic pathway of irinotecan: transporters
- Limitation of previous studies
- Conclusions
Topics Covered
- Irinotecan activity and safety
- Metabolism of Irinotecan
- Structure of UGT1A
- Role of UGT1A1*28 on irinotecan pharmacogenetics
- Role of UGT1A1*6 in Asians
- Genotype-based dosing of irinotecan
- Other candidates: UGT1A enzyme or transporter
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kim, T.W. (2009, January 6). UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/OYXV2220.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tae Won Kim has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients
A selection of talks on Clinical Practice
Hide